Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorobenzene SCHEMBL7260822 | 0.91 | CTBP2 (0.51) | CTBP2KMT2AMEN1MAPTSHBG | |
| SCHEMBL6767819 | 0.84 | AKR1B1 (0.46) | CTBP2ALDH1A1NPC1RAB9APTGS2 | |
| SCHEMBL7405623 | 0.83 | P2RX7 (0.44) | CTBP2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL158861 | 0.83 | CTBP2 (0.55) | CTBP2KMT2AMEN1MAPTSHBG | |
| SCHEMBL29718576 | 0.83 | CTBP2 (0.55) | CTBP2KMT2AMEN1MAPTSHBG | |
| SCHEMBL2935824 | 0.82 | CTBP2 (0.58) | CTBP2KMT2AMEN1MAPTSHBG | |
| Hydrochloric Acid SCHEMBL14167478 | 0.81 | CTBP2 (0.53) | CTBP2KMT2AMEN1MAPTSHBG | |
| SCHEMBL24977628 | 0.80 | GABRA1 (0.44) | SHBGALDH1A1PTGS2 | |
| SCHEMBL2528595 | 0.80 | AKR1B1 (0.61) | CTBP2KMT2AMEN1MAPTSHBG | |
| SCHEMBL8285 | 0.80 | AKR1B1 (0.61) | CTBP2KMT2AMEN1MAPTSHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111635435-B | Bivalent copper complex containing biphosphine ortho-carborane ligand, and preparation method and application thereof | 上海应用技术大学 | 2023-04-28 | — | — | CN | claimed |
| EP-1931693-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2008-06-18 | — | — | EP | claimed |
| WO-2007027564-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-03-08 | — | — | WO | claimed |
| CN-119528934-A | 2-Pyridothiophene compound, preparation method, application and antitubercular drug thereof | 桂林医学院 | 2025-02-28 | — | — | CN | disclosed |
| CN-119241469-A | Photoinitiator, photopolymerization composition and application thereof | 武汉尚赛光电科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| EP-4430026-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240000075-A1 | FUNGICIDAL ARYL AMIDINES | CORTEVA AGRISCIENCE LLC (US) | 2024-01-04 | — | — | US | disclosed |
| CN-117024298-A | Tertiary amide compound containing naphthyl and its preparation method and application | 北京中医药大学 | 2023-11-10 | — | — | CN | disclosed |
| EP-4247788-A1 | FUNGICIDAL ARYL AMIDINES | Corteva Agriscience LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-4210749-A | USED AS ANALGESICS, NARCOTIC ANTAGONISTS | PENNWALT CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
| US-4200572-A | Substituted azetidinones | SMITHKLINE CORPORATION (US) | 1980-04-29 | — | — | US | disclosed |
| US-4148918-A | APHICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4115584-A | Substituted 2-higher alkyl-3-hydroxy-1,4-naphthoquinone carboxylic acid esters and their use as miticides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4086423-A | CEPHALOSPORINS, CYCLOADDITION OF GLYCINE DERIVATIVE TO THIAZINE COMPOUND | MERCK & CO., INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4070481-A | Substituted 2-higher alkyl-3-hydroxy-1,4-naphthoquinone carboxylic acid esters and their use as miticides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-01-24 | — | — | US | disclosed |
| US-4008276-A | ANTIINFLAMMATORY | STERLING DRUG INC. (US) | 1977-02-15 | — | — | US | disclosed |
| US-4000154-A | 3-Substituted-6β-(amino- and acylamino)-7-oxo-1,3-diazabicyclo[3.2.0]-h | SMITHKLINE CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-3965105-A | ANTIINFLAMMATORY | STERLING DRUG INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000075-A1 | FUNGICIDAL ARYL AMIDINES | CYP1A1, CYP1A2, CYP1B1 | CTBP2 3916/4885KMT2A 1220/4885MEN1 1445/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | CTBP2 2980/4885KMT2A 2558/4885MEN1 3285/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | CTBP2 3253/4885KMT2A 2174/4885MEN1 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.